Ovarian Cancer

Non-small cell lung cancer (brca)

In the United States, the estimated

number of new cases of OC for

2019 is >22,000.1

The 5-year survival rate

for metastatic OC is

<30%1

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommend:

 

  • BRCA1/2 mutation testing for patients with histologically confirmed OC2 
  • Tumor molecular testing for patients with recurrent OC, including at least BRCA1/2, and MSI or MMR if not previously done. Evaluation of HRR deficiency can be considered.2

BRCA, breast cancer susceptibility gene; MMR, mismatch repair; HRR, homologous recombination repair; MSI, microsatellite instability; NCCN, National Comprehensive Cancer Network; OC, ovarian cancer.

References: 1. Cancer Facts and Figures 2019. American Cancer Society; 2019. 2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer V1.2020. © National Comprehensive Cancer Network, Inc. 2020. All rights reserved. Accessed March 16, 2020. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.